Fractyl Health, Inc. (NASDAQ:GUTS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have been assigned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $7.40.

A number of analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a research report on Wednesday, October 8th. LADENBURG THALM/SH SH started coverage on Fractyl Health in a research report on Thursday, August 28th. They set a “buy” rating and a $3.60 price target on the stock. Canaccord Genuity Group upped their price objective on Fractyl Health from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 21st. Finally, HC Wainwright decreased their target price on shares of Fractyl Health from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, September 26th.

Fractyl Health Price Performance

Shares of GUTS stock opened at $1.48 on Friday. The company has a quick ratio of 4.27, a current ratio of 4.27 and a debt-to-equity ratio of 4.61. Fractyl Health has a 12-month low of $0.83 and a 12-month high of $3.03. The firm has a fifty day moving average of $1.28 and a 200-day moving average of $1.46. The firm has a market capitalization of $202.82 million, a price-to-earnings ratio of -0.65 and a beta of 2.20.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Wednesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). On average, equities research analysts forecast that Fractyl Health will post -1.61 earnings per share for the current year.

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors have recently made changes to their positions in the company. Woodline Partners LP increased its position in Fractyl Health by 821.1% during the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock worth $8,755,000 after acquiring an additional 4,908,693 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of Fractyl Health during the 3rd quarter worth approximately $8,981,000. Scientech Research LLC bought a new position in shares of Fractyl Health during the third quarter worth approximately $49,000. Prelude Capital Management LLC acquired a new stake in shares of Fractyl Health in the third quarter valued at approximately $55,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Fractyl Health in the third quarter valued at approximately $19,298,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.